



(51) International Patent Classification:

A61K 9/22 (2006.01) A61K 9/14 (2006.01)  
A61K 9/20 (2006.01) A61K 31/66 (2006.01)  
A61K 9/16 (2006.01)

(21) International Application Number:

PCT/US2012/033671

(22) International Filing Date:

13 April 2012 (13.04.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/475,844 15 April 2011 (15.04.2011) US

(71) Applicant (for all designated States except US):

**THRESHOLD PHARMACEUTICALS, INC.** [US/US];  
170 Harbour Way, Suite 300, South San Francisco, California 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **JUNG, Donald**

[US/US]; c/o Threshold Pharmaceuticals, Inc., 170 Harbor Way, Suite 300, South San Francisco, California 94080 (US). **MATTEUCCI, Mark** [US/US]; c/o Threshold Pharmaceuticals, Inc., 170 Harbor Way, Suite 300, South

San Francisco, California 94080 (US). **KROLL, Stewart** [US/US]; c/o Threshold Pharmaceuticals, Inc., 170 Harbor Way, Suite 300, South San Francisco, California 94080 (US).

(74) Agents: **KONSKI, Antoinette F.** et al.; Foley & Lardner

LLP, 975 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: UNIT DOSE FORM FOR ORAL ADMINISTRATION

FIG. 1.



(57) Abstract: Formulations and unit dose forms of TH-302 and other hypoxia activated prodrugs suitable for oral administration are useful for treating cancer.

WO 2012/142520 A3

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *with international search report (Art. 21(3))*

**Declarations under Rule 4.17:**

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**(88) Date of publication of the international search report:**  
3 January 2013

**A. CLASSIFICATION OF SUBJECT MATTER***A61K 9/22(2006.01)i, A61K 9/20(2006.01)i, A61K 9/16(2006.01)i, A61K 9/14(2006.01)i, A61K 31/66(2006.01)i*

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K 9/22; A61K 31/685; A61K 39/395; A61K 31/4168; A61K 31/35; C07F 9/02; A01N 43/54; A61K 31/535; A61K 31/506; G01N 33/574; A61K 31/4164

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models  
Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) &amp; Keywords: hypoxia activated prodrug, TH-302, oral, formulation, modified-release, structure of Formula (I)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2008-083101 A1 (THRESHOLD PHARMACEUTICALS, INC.) 10 July 2008 See abstract, p. 2, and claims 1-7, 14.	1-10, 12, 13
Y	WO 2007-002931 A2 (THRESHOLD PHARMACEUTICALS, INC.) 04 January 2007 See abstract, paragraphs [0006], [0324], [0325], and claims 1-42.	1-10, 12, 13
A	WO 2010-048330 A1 (THRESHOLD PHARMACEUTICALS, INC.) 29 April 2010 See abstract and claims 1, 9, 15, 17, 19.	1-10, 12, 13
A	US 05472956 A (R. F. BORCH et al.) 05 December 1995 See abstract and claims 1-3.	1-10, 12, 13
PX	WO 2012-009288 A2 (THRESHOLD PHARMACEUTICALS, INC.) 19 January 2012 See paragraphs [0009], [0069], [0070] and claims 1, 4.	1
PA	WO 2012-006032 A2 (THRESHOLD PHARMACEUTICALS, INC.) 12 January 2012 See paragraphs [0007], [0042], [0082] and claims 1, 6, 7.	1-10, 12, 13

 Further documents are listed in the continuation of Box C. See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

11 OCTOBER 2012 (11.10.2012)

Date of mailing of the international search report

**12 OCTOBER 2012 (12.10.2012)**

Name and mailing address of the ISA/KR

Korean Intellectual Property Office  
189 Cheongsu-ro, Seo-gu, Daejeon Metropolitan  
City, 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

LEE, SUN HWA

Telephone No. 82-42-481-5606



**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2012/033671**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2008-083101 A1	10.07.2008	EP 2114157 A1	11.11.2009
		JP 2010-514787 A	06.05.2010
		JP 2010-514787 T	06.05.2010
		US 2010-0183742 A1	22.07.2010
WO 2007-002931 A2	04.01.2007	AU 2006-263433 A1	04.01.2007
		AU 2006-263433 B2	02.06.2011
		AU 2006-263433 B8	09.06.2011
		AU 2011-202075 A1	26.05.2011
		BR PI 0612845 A2	30.11.2010
		CA 2613312 A1	04.01.2007
		CN 101501054 A	05.08.2009
		EP 1896040 A2	12.03.2008
		EP 1896040 A4	10.02.2010
		EP 1896040 B1	01.08.2012
		EP 2336141 A2	22.06.2011
		EP 2336141 A3	14.09.2011
		IL 188236 D0	07.08.2008
		JP 2009-502743 A	29.01.2009
		JP 2009-502743 T	29.01.2009
		JP 2012-153722 A	16.08.2012
		KR 10-2008-0027901 A	28.03.2008
		NO 20080442 A	31.03.2008
		NZ 565378 A	31.03.2011
		RU 2008103195 A	10.08.2009
		RU 2414475 C2	20.03.2011
		TW 200800228 A	01.01.2008
		US 2010-0137254 A1	03.06.2010
US 2011-251159 A1	13.10.2011		
US 8003625 B2	23.08.2011		
WO 2007-002931 A3	23.04.2009		
ZA 200800314 A	30.09.2009		
WO 2010-048330 A1	29.04.2010	EP 2350664 A1	03.08.2011
		JP 2012-506448 A	15.03.2012
US 05472956 A	05.12.1995	EP 0697022 A1	21.02.1996
		JP 08-509727 A	15.10.1996
		US 05306727 A	26.04.1994
		WO 94-25471 A1	10.11.1994
WO 2012-009288 A2	19.01.2012	None	
WO 2012-006032 A2	12.01.2012	None	

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 19  
because they relate to subject matter not required to be searched by this Authority, namely:  
Claim 19 is directed to a treatment method of the human body by therapy under Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT.
2.  Claims Nos.: 16-18  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Claim 16-18 are unclear under PCT Article 6, because they refer to claim 15 which is not drafted in accordance with the third sentence of PCT Rule 6.4(a).
3.  Claims Nos.: 11, 14, 15, 19  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.